Kausik Chatterjee

Prof. Kausik Chatterjee


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in IEEE Transactions on Neural Systems and Rehabilitation Engineering
Verified
Journal Article
Open access
KCKausik Chatterjee
Kausik Chatterjee
ABAlastair Buchanan
Alastair Buchanan
KCKaty Cottrell
Katy Cottrell
SHSara Hughes
Sara Hughes
TDThomas W. Day
Thomas W. Day
NJNigel W. John
Nigel W. John
We present the results of a double-blind phase 2b randomized control trial that used a custom built virtual reality environment for the cognitive rehabilitation of stroke survivors. A stroke causes damage to the brain and problem solving, memory and task sequencing are commonly affected. The brain can recover to some extent, however, and stroke patients have to relearn how to carry out activities of daily living. We have created an application called VIRTUE to enable such activities to be practiced using immersive virtual reality. Gamification techniques enhance the motivation of patients such as by making the level of difficulty of a task increase over time. The design and implementation of VIRTUE is described together with the results of the trial conducted within the Stroke Unit of a large hospital. We report on the safety and acceptability of VIRTUE. We have also observed particular benefits of VR treatment for stroke survivors that experienced more severe cognitive impairment, and an encouraging reduction in time spent in the hospital for all patients that received the VR treatment.

1 July 2019 in Trials
Verified
Journal Article
Open access
PDF file
KCKausik Chatterjee
Kausik Chatterjee
RSRachel Stockley
Rachel Stockley
SLSteven Lane
Steven Lane
DWDame Caroline Watkins
Dame Caroline Watkins
KCKaty Cottrell
Katy Cottrell
TNTuro Nurmikko
Turo Nurmikko
Reduction in sensorimotor function of the upper limb is a common and persistent impairment after stroke, and less than half of stroke survivors recover even basic function of the upper limb after a year. Previous work in stroke has shown that repetitive sensory stimulation (RSS) of the upper limb may benefit motor function. As yet, there have been no investigations of RSS in the early-acute period despite this being the time window during which the neuroplastic processes underpinning sensorimotor recovery are likely to occur. A single-blinded, stratified, randomised controlled feasibility study was undertaken at two NHS acute trusts to determine the recruitment rate, intervention adherence, and safety and acceptability of an RSS intervention in the early period after stroke. Participants were recruited within 2 weeks of index stroke. Stratified on arm function, they were randomised to receive either 45 min of daily RSS and usual care or usual care alone (UC) for 2 weeks. Changes from baseline on the primary outcome of the Action Research Arm Test (ARAT) to measurements taken by a blinded assessor were examined after completion of the intervention (2 weeks) and at 3 months from randomisation. Forty patients were recruited and randomised (RSS n = 23; UC n = 17) with a recruitment rate of 9.5% (40/417) of patients admitted with a stroke of which 52 (12.5%) were potentially eligible, with 10 declining to participate for various reasons. Participants found the RSS intervention acceptable and adherence was good. The intervention was safe and there were no serious adverse events. This study indicates that recruitment to a trial of RSS in the acute period after stroke is feasible. The intervention was well tolerated and appeared to provide additional benefit to usual care. In addition to a definitive trial of efficacy, further work is warranted to examine the effects of varying doses of RSS upon arm function and the mechanism by which RSS induces sensorimotor recovery in the acute period after stroke. ISRCTN, registry no: ISRCTN17422343 ; IRAS Project ID: 215137. Registered on October 2016

12 May 2026 in Neurology
Verified
Journal Article
Closed access
AGAravind Ganesh
Aravind Ganesh
SVShabnam Vatanpour
Shabnam Vatanpour
AYAmy Ying Xin Yu
Amy Ying Xin Yu
PBPhilip Barber
Philip Barber
PCPhilip Man Chiu Choi
Philip Man Chiu Choi
SCShelagh B. Coutts
Shelagh B. Coutts
There are few high-quality data on thrombolysis outcomes in the oldest patients, especially for minor stroke. We examined safety and efficacy outcomes of thrombolysis in patients older than 80 years, compared with those ≤80 years, in the Tenecteplase Versus Standard of care for Minor Ischaemic Stroke With Proven Occlusion (TEMPO-2) trial. In this post hoc analysis of the TEMPO-2 randomized controlled trial, we compared outcomes and adverse events in patients with minor stroke and symptomatic intracranial occlusion or focal perfusion lesion within 12 hours of symptom onset, assigned to tenecteplase vs nonthrombolytic standard of care, in those >80 years and ≤80 years. The primary outcome was responder analysis of the 90-day modified Rankin Scale (responder was mRS = 0-1 if premorbid mRS = 0-1, 0-2 if premorbid mRS = 2). Secondary outcomes included neurologic recovery according to the NIH Stroke Scale (NIHSS) at 5 days/discharge, vessel recanalization, Lawton Instrumental Activities of Daily Living Scale, EuroQol-5 Dimension (EQ-5D), and adverse events. We used mixed-effects Poisson, ordinal logistic, and quantile regression as appropriate, adjusted for sex, baseline NIHSS, and treatment assignment as fixed-effects and enrolling site as random effects. Among 884 patients in the intention-to-treat analysis (208 [23.5%] >80 years, 365 [41.6%] female). Significant interactions between age and treatment were observed for mRS responder, mRS 0-1, return to baseline function, EQ-5D index, and vessel recanalization. Patients >80 years generally fared worse with tenecteplase for mRS outcomes (mRS 0-1 in 49 [46.2%] vs 61 [59.8%] with control, adjusted risk ratio [aRR] 0.83, 95% CI 0.72-0.97), while among patients ≤80 years, there was no significant difference (249 [76.4%] vs 260 [74.7%], aRR 1.01, 95% CI 0.98-1.03). However, in both age groups, patients were more likely to achieve recanalization of visible occlusions (aRR ≤80 years 2.06, 95% CI 1.60-2.65, >80 years 2.77, 95% CI 2.21-3.47) and NIHSS = 0 at 5 days/discharge when assigned to tenecteplase (aRR ≤80 years 1.14, 95% CI 1.04-1.26, >80 years 1.21, 95% CI 1.10-1.33). Serious adverse events (SAEs) were more frequent with tenecteplase among patients >80 years (risk ratio 2.29, 95% CI 1.27-4.13), particularly hemorrhages and stroke progression/recurrence (any extra/intracranial hemorrhage in 5 [4.7%] vs 0 with standard of care, p = 0.026). Older patients (>80 years) with minor stroke and visible occlusion or perfusion lesion assigned to tenecteplase were more likely to achieve recanalization of occlusions and short-term neurologic recovery, as were younger patients, but they experienced worse 90-day outcomes with more frequent hemorrhagic and stroke progression/recurrence-related SAEs. Overall, these results, while post hoc, do not support thrombolysis for minor strokes in older patients. ClinicalTrials.gov: NCT02398656. This study provides Class III evidence that in patients >80 years with minor stroke and visible occlusion or perfusion lesion, IV thrombolysis with tenecteplase is associated with worse functional outcomes at 90 days compared with nonthrombolytic standard of care therapies.

17 December 2019 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
EBEmma P. Bray
Emma P. Bray
NMNaoimh E. McMahon
Naoimh E. McMahon
MBMunirah Bangee
Munirah Bangee
AAA. Hakam Al-Khalidi
A. Hakam Al-Khalidi
VBValerio Benedetto
Valerio Benedetto
DWDame Caroline Watkins
Dame Caroline Watkins
Background: Stroke is a leading cause of death and disability worldwide. Identifying the aetiology of ischaemic stroke is essential in order to initiate appropriate and timely secondary prevention measures to reduce the risk of recurrence. For the majority of ischaemic strokes, the aetiology can be readily identified, but in at least 30% of cases, the exact aetiology cannot be determined using existing investigative protocols. Such strokes are classed as ‘cryptogenic’ or as a stroke of unknown origin. However, there exists substantial variation in clinical practice when investigating cases of seemingly cryptogenic stroke, often reflecting local service availability and the preferences of treating clinicians. This variation in practice is compounded by the lack of international consensus as to the optimum level and timing of investigations required following a stroke. To address this gap, we aim to systematically review and compare recommendations in evidence-based clinical practice guidelines (CPGs) that relate to the assessment and investigation of the aetiology of ischaemic stroke, and any subsequent diagnosis of cryptogenic stroke. Method: We will search for CPGs using electronic databases (MEDLINE, Health Management Information Consortium (HMIC), EMBASE, and CINAHL), relevant websites and search engines (e.g. guideline specific websites, governmental, charitable, and professional practice organisations) and hand-searching of bibliographies and reference lists. Two reviewers will independently screen titles, abstracts and CPGs using a pre-defined relevance criteria form. From each included CPG, we will extract definitions and terms for cryptogenic stroke; recommendations related to assessment and investigation of the aetiology of stroke, including the grade of recommendations and underpinning evidence. The quality of the included CPGs will be assessed using the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool. Recommendations across the CPGs will be summarised descriptively highlighting areas of convergence and divergence between CPGs. Discussion: To our knowledge, this will be the first review to systematically compare recommendations of international CPGs on investigating the aetiology of ischaemic stroke. The findings will allow for a better understanding of international perspectives on the optimum level of investigations required following a stroke and thus contribute to achieving greater international consensus on best practice in this important and complex area. Systematic review registration: PROSPERO CRD42019127822.

17 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KCKausik Chatterjee
Kausik Chatterjee
SLSandra Leason
Sandra Leason
AHAllam Harfoush
Allam Harfoush
YAYashika Arora
Yashika Arora
Anirban DuttaAnirban Dutta
Anirban Dutta
Background: Enhancing cerebral perfusion after stroke may aid recovery, but individual responsiveness to neuromuscular electrical stimulation (NMES) remains unclear. Objective: To identify predictors of cerebral hemodynamic response to common peroneal NMES in subacute stroke. Methods: In this observational study (RETRAIN Phase 1, NCT06614400), 18 patients underwent functional near-infrared spectroscopy (fNIRS) during NMES at varying postures and intensities. Responders were defined by top-quartile increases in oxygenated hemoglobin (HbO). Predictors were assessed using AUROC screening and LASSO logistic regression with crossvalidation. Results: The final model (AUROC = 0.723) retained 13 predictors, including cortical lesion location (OR = 1.66), atrial fibrillation (OR = 1.28), and ASPECTS thalamic and caudate involvement. Permutation analysis confirmed predictor robustness. Conclusion: This study demonstrates a clinically interpretable machine learning framework to stratify stroke patients by NMES responsiveness. Larger studies with outcome validation are warranted.

30 October 2026 in Clinical Rehabilitation
Verified
Journal Article
Open access
FRFiona J Rowe
Fiona J Rowe
JDJacob Davies
Jacob Davies
KDKodchawan Doungsong
Kodchawan Doungsong
EBElla Brayshaw
Ella Brayshaw
MBMichaela Brown
Michaela Brown
RERhiannon Tudor Edwards
Rhiannon Tudor Edwards
Objective: To explore the cost-effectiveness of visual scanning training for hemianopia compared to sham training. Design: Randomised controlled trial. Setting: Acute stroke unit and outpatient eye clinics. Participants: Adult stroke survivors with homonymous hemianopia. Intervention: Visual scanning training. Comparator: Sham eye pursuit movements. Main measures: Cost-utility and cost-effectiveness analyses were conducted from UK National Health Service (NHS) and wider societal perspectives. The primary analysis was a cost-utility analysis using EQ-5D-5L utility values. Cost-effectiveness analyses using changes in National Eye Institute-Visual Function Questionnaire-25 item composite and Brain Injury-associated Visual Impairment-Impact Questionnaire scores formed the secondary analyses. Results: Both intervention and sham training packages cost £9.58 (printing costs, clinician time to explain self-administration). Mean total health resource use costs at 26-weeks were higher in the intervention (£1406) than in the sham group (£1339). At 26-weeks, the intervention group gained 0.001 (95%CI:-0.018, 0.021) Quality-Adjusted Life Years (QALY) while the sham group evidenced a QALY loss of −0.002 (95%CI:-0.017, 0.012); not statistically significant (p = 0.71). The Incremental Cost-Effectiveness Ratio of visual scanning training compared to sham was £19,790/QALY, below the National Institute for Health and Care Excellence (NICE) threshold of £20,000–£30,000/QALY. Sensitivity analysis (5000 replications) suggested potential cost-effectiveness of visual scanning training, which had a 67% probability of being cost-effective at £20,000/QALY; this was not significant. Conclusions: This is the first economic evaluation comparing visual scanning training to sham training for treating post-stroke hemianopia. While both interventions had similar costs, the costs were slightly under NICE thresholds. The intervention evidenced marginal but non-significant QALY gain over sham.